(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Arctic is again the hottest it's been in 125 years, with record-low sea ice, NOAA report says - 22 of Earth's rarest lightning phenomena captured simultaneously in once-in-a-lifetime photo
- 3Before trips to Mars, we need better protection from cosmic rays
- 4Europe’s EV Boom Was Real in 2025. The Real Fight Starts In 2026
- 5Pick Your Favored method of transportation
- Benin coup thwarted by loyalist troops, president tells nation
- Yasser Abu Shabab's killing raises questions about Israel's militia strategy in Gaza
- Toyota Motor Europe to roll out smart EV charging through new partnerships
- Turkey, Egypt, Qatar discuss second phase of Gaza ceasefire deal
- More people are addicted to marijuana, but fewer of them are seeking help, experts say
- Vote in favor of your Number one Kind of Shades
- NASA's Perseverance Mars rover could break the record for miles driven on another planet
- An Extended time of Careful Nurturing: Individual Bits of knowledge on Bringing up Kids
- Which Switch Game Do You Suggest? Share Your Decision
